Patient-centered trials in oncology: Time for a change
- PMID: 35809559
- DOI: 10.1016/j.medj.2022.06.007
Patient-centered trials in oncology: Time for a change
Abstract
Patient-centered trials are pivotal to advancing the oncology field efficiently. However, in recent years, there has been a shift away from patient-centered approaches. In this commentary, we describe common non-patient-centric practices of contemporary trials, discuss their implications, and propose potential solutions to relocate patients to the center of trials where they belong.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.V.A. has an advisory role for MSD and receives honoraria from MSD, Pfizer, GSK, and Libbs. J.A.D. declares no competing interests. V.C.C.L. has an advisory role for MSD, Astra-Zeneca, Lilly, and Janssen; receives honoraria from Amgen, Sanofi, Astra-Zeneca, BMS, MSD, Lilly, Janssen, and Roche; and serves as a consultant for Grupo Hermes Pardini – Medicina de Precisão.
MeSH terms
LinkOut - more resources
Full Text Sources